CDFR 0111Alternative Names: CDFR0111; Esomeprazole/naproxen - CTCBIO
Latest Information Update: 01 Sep 2016
At a glance
- Originator CTCBIO
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Connective tissue disorders; Musculoskeletal disorders